• Explore /
  • Poster
  • / Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

Abstract Poster

Authors

null

Weimin Li

Janssen Research and Development, Spring House, PA

Weimin Li , Joyce O'Shaughnessy , Deborah Sokol Ricci , Thomas W. Griffin , Thian San Kheoh , Margaret K. Yu , Michael Gormley , Jason L. Martin , Michael Schaffer , Kathy Zelinsky , Daniel F. Hayes , Mario Campone , Igor Bondarenko , Irina Zbarskaya , Etienne Brain , Marina B. Stenina , Olga Ivanova , Marie-Pascale Graas , Patrick Neven , Stephen R. D. Johnston

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

ER+

Clinical Trial Registration Number

NCT01381874

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 520)

DOI

10.1200/jco.2014.32.15_suppl.520

Abstract #

520

Poster Bd #

9

Abstract Disclosures

Similar Posters

First Author: Joyce O'Shaughnessy

First Author: Joyce O'Shaughnessy

First Author: Jacqueline M Dempsey

First Author: Daniella Audi Blotta